Year: 2022

Dr. Hafrun Fridriksdottir Dr. Hafrun Fridriksdottir new Chief Operating Officer of AlvotechRobert Wessman Mr. Robert Wessman Executive Chairman and Founder of Alvotech who will also be assuming the position of Chief Executive OfficerHafrun Fridriksdottir, previously Executive VP and Head of Global R&D at Teva, will become Chief Operating OfficerMark Levick has decided to step down as Chief Executive Officer and Robert Wessman, Executive Chairman and founder, will become CEOChanges to the leadership team are effective January 1, 2023REYKJAVIK, Iceland, Dec. 01, 2022 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to its leadership team. Mark Levick, Chief Executive Officer...

Hafrun Fridriksdottir, previously Executive VP and Head of Global R&D at Teva, will become Chief Operating Officer Mark Levick has decided to step down as Chief Executive Officer and Robert Wessman, Executive Chairman and founder, will become CEO Changes to the leadership team are effective January 1, 2023Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to its leadership team. Mark Levick, Chief Executive Officer has decided to step down and Robert Wessman, Executive Chairman and founder will become CEO, leading the next phase of growth. Hafrun Fridriksdottir, previously Executive Vice President and Head of Global R&D at Teva, has been appointed Chief Operating Officer. Changes to the leadership team are...

CINCINNATI, Dec. 01, 2022 (GLOBE NEWSWIRE) — Paycor HCM, Inc. (Nasdaq: PYCR) (“Paycor”), a leading provider of human capital management (HCM) software, today announced the commencement of an underwritten public offering of 5,000,000 shares of common stock on behalf of investment funds advised by Apax Partners LLP. The offering consists of 3,531,941 shares offered by Pride Feeder, L.P. and 1,468,059 shares offered by AIX Pride Syndication, L.P., respectively. Each of the selling stockholders are controlled by investment funds advised by Apax Partners LLP. Paycor will not receive any of the proceeds from the sale of the shares being offered by the selling stockholders but will bear the costs associated with the sale of such shares, other than any underwriting discounts and commissions. Goldman Sachs & Co. LLC is acting as underwriter...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS VANCOUVER, British Columbia, Dec. 01, 2022 (GLOBE NEWSWIRE) — Prime Mining Corp. (“Prime”, or the “Company”) (TSX.V: PRYM, OTCQB: PRMNF, Frankfurt: A2PRDW) is pleased to announce that it has entered into an agreement with Desjardins Capital Markets, acting as sole bookrunner and co-lead, on behalf of a syndicate of underwriters co-led by Desjardins Capital Markets and TD Securities Inc. (the “Co-Leads Underwriters” and collectively, the “Underwriters”) whereby the Underwriters have agreed to purchase for resale, on a bought deal private placement basis, 11,000,000 units (the “Units”) at a price of $1.50 per Unit for gross proceeds of...

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) — Mobiquity Technologies, Inc. (Nasdaq: MOBQ) (the “Company”), a leading provider of next-generation data intelligence and advertising technologies, announces that on November 25, 2022, it received a deficiency notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of its noncompliance with the Nasdaq Listing Rule 5250 (c)(1) due to its failure to file its Form 10-Q for the period ended September 30, 2022. Under Nasdaq’s Rules, the Company has 60 calendar days to submit a plan to regain compliance. It is anticipated that the Form 10-Q will be filed by the Company on or about December 9, 2022. As more fully described in the recently filed Form 8-K, the Audit Committee of the Company and its prior independent public accountant,...

PRESS RELEASE Boston, MA U.S.A. (December 1, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that the Company’s adjourned 2022 Annual Stockholders Meeting (“2022 ASM”) set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting (“2023 ASM”) will be held, as a virtual meeting, on January 19, 2023. As previously announced, the Company’s 2022 ASM on November 4, 2022 was adjourned to December 2, 2022, without any business being conducted to allow additional time to achieve quorum and for stockholders to vote on the proposals set forth in the Company’s definitive proxy statement filed with the U.S. Securities...